Benjamin F. Edwards & Company’s Genmab GMAB Stock Holding History

Benjamin F. Edwards & Company’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$182K	Buy	7,227 +478	+7%	+$13.6K	﹤0.01%	935
2024 Q1	$202K	Sell	6,749 -36	-0.5%	-$1.06K	﹤0.01%	905
2023 Q4	$216K	Buy	+6,785	New	+$213K	﹤0.01%	859
2022 Q1	–	Sell	-74	Closed	-$3K	–	1779
2021 Q4	$3K	Hold	74	–	–	﹤0.01%	1594
2021 Q3	$3K	Hold	74	–	–	﹤0.01%	1592
2021 Q2	$3K	Hold	74	–	–	﹤0.01%	1579
2021 Q1	$2K	Hold	74	–	–	﹤0.01%	1616
2020 Q4	$3K	Buy	+74	New	+$2.77K	﹤0.01%	1480

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Benjamin F. Edwards & Company's GMAB Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Genmab (GMAB) stake by 7.1% in Q2 2024, buying an estimated $13.6K and bringing the position to 7,227 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #935.

Benjamin F. Edwards & Company first reported a position in GMAB in Q4 2020 and has held it in 8 quarters since. The position peaked at $216K in Q4 2023. 220 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

Benjamin F. Edwards & Company held 7,227 shares of Genmab worth $182K as of Q2 2024.
Benjamin F. Edwards & Company bought 478 Genmab shares in Q2 2024, an estimated $13.6K.
Genmab made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #935 holding.
Benjamin F. Edwards & Company first reported a position in Genmab in Q4 2020 and has held it in 8 quarters since.
Benjamin F. Edwards & Company's Genmab position peaked at $216K in Q4 2023.
220 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.